Development and In Vitro Evaluation of 5-Fluorouracil-Eluting Stents for the Treatment of Colorectal Cancer and Cancer-Related Obstruction.

5-fluorouracil dip-coating drug-eluting stent gastrointestinal cancer localised drug delivery

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
24 Dec 2020
Historique:
received: 01 12 2020
revised: 17 12 2020
accepted: 19 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 31 12 2020
Statut: epublish

Résumé

Self-expanding metal stents (SEMSs) are currently the gold standard for the localised management of malignant gastrointestinal (GI) stenosis and/or obstructions. Despite encouraging clinical success, in-stent restenosis caused by tumour growth is a significant challenge. Incorporating chemotherapeutic drugs into GI stents is an emerging strategy to provide localised and sustained release of drugs to intestinal malignant tissues to prevent tumour growth. Therefore, the aim of this work was to develop and evaluate a local GI stent-based delivery system that provides a controlled release of 5-fluorouracil (5FU) over a course of several weeks to months, for the treatment of colorectal cancer and cancer-related stenosis/obstructions. The 5FU-loaded GI stents were fabricated via sequential dip-coating of commercial GI stents with a drug-loaded polyurethane (PU) basecoat and a drug-free poly(ethylene-

Identifiants

pubmed: 33374233
pii: pharmaceutics13010017
doi: 10.3390/pharmaceutics13010017
pmc: PMC7823773
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Pharm. 2009 Jun 5;374(1-2):53-7
pubmed: 19446759
J Diabetes Sci Technol. 2014 May;8(3):581-9
pubmed: 24876623
Gels. 2018 May 03;4(2):
pubmed: 30674817
Cancer Res. 2001 Feb 1;61(3):1029-37
pubmed: 11221829
Sci Rep. 2018 Jan 10;8(1):288
pubmed: 29321581
Gastrointest Endosc. 2005 Feb;61(2):296-301
pubmed: 15729251
Curr Opin Gastroenterol. 2007 Sep;23(5):544-9
pubmed: 17762561
Gastrointest Endosc. 2009 May;69(6):1140-7
pubmed: 19243763
Adv Ther. 2011 Feb;28(2):73-86
pubmed: 21229339
Clin Endosc. 2015 May;48(3):209-15
pubmed: 26064820
J Control Release. 2019 Aug 28;308:209-231
pubmed: 31279817
Oncotarget. 2014 Sep 15;5(17):7691-704
pubmed: 25277198
Gastrointest Endosc. 2015 Jul;82(1):153-160.e1
pubmed: 25936448
Eur J Pharm Biopharm. 2012 Apr;80(3):562-70
pubmed: 22209978
J Pharm Sci. 2010 Jul;99(7):3009-18
pubmed: 20091819
Endoscopy. 2012 Sep;44(9):825-31
pubmed: 22752887
Biomaterials. 2006 Apr;27(11):2450-67
pubmed: 16337266
J Gastroenterol Hepatol. 2012 Feb;27(2):261-7
pubmed: 21793905
Int J Surg. 2011;9(8):595-9
pubmed: 21930255
Circ Cardiovasc Interv. 2016 Jun;9(6):
pubmed: 27193905
Infect Immun. 2005 Apr;73(4):1907-16
pubmed: 15784530
Int J Nanomedicine. 2017 Oct 17;12:7669-7680
pubmed: 29089762
Nanomicro Lett. 2016;8(3):260-269
pubmed: 30460286
Int J Pharm. 2012 Oct 15;436(1-2):272-81
pubmed: 22721846
J Biomater Appl. 2015 Mar;29(8):1133-44
pubmed: 25252589
Pharmaceutics. 2020 May 11;12(5):
pubmed: 32403329
J Biomed Mater Res B Appl Biomater. 2012 May;100(4):891-5
pubmed: 22438332
World J Gastroenterol. 2016 Jan 14;22(2):842-52
pubmed: 26811630
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346376
Int J Pharm. 2012 May 10;427(2):276-83
pubmed: 22366483
Adv Pharmacol Sci. 2018 Dec 27;2018:4751806
pubmed: 30687400
Biomed Microdevices. 2014 Dec;16(6):897-904
pubmed: 25135441
Biomater Res. 2014 Oct 08;18:15
pubmed: 26331066
Int J Nanomedicine. 2013;8:1697-711
pubmed: 23658488
Cell Div. 2010 Jan 21;5:4
pubmed: 20205872
Clin Endosc. 2013 Jul;46(4):355-67
pubmed: 23964332
Polymers (Basel). 2019 Jun 17;11(6):
pubmed: 31212957
Biomaterials. 2015;53:592-9
pubmed: 25890755
J Pharmacol Toxicol Methods. 2015 Jan-Feb;71:68-76
pubmed: 25157754
Saudi Pharm J. 2017 Feb;25(2):206-213
pubmed: 28344470
Endoscopy. 2020 May;52(5):389-407
pubmed: 32259849
Drug Test Anal. 2009 May;1(5):240-4
pubmed: 20355202
Dent Mater. 2007 Apr;23(4):404-9
pubmed: 16556460
AAPS PharmSciTech. 2017 Feb;18(1):130-137
pubmed: 26895019
J Control Release. 2007 Apr 23;118(3):318-24
pubmed: 17289208
J Control Release. 2016 Sep 28;238:231-241
pubmed: 27288878
J Control Release. 2010 Aug 17;146(1):45-53
pubmed: 20566400
Clin Endosc. 2015 May;48(3):194-200
pubmed: 26064818
Saudi Pharm J. 2019 Dec;27(8):1164-1173
pubmed: 31885476
Biomaterials. 2011 May;32(14):3603-10
pubmed: 21334742
Biomaterials. 2013 Dec;34(37):9451-61
pubmed: 24011711

Auteurs

Mohammad Arafat (M)

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Paris Fouladian (P)

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Anthony Wignall (A)

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Yunmei Song (Y)

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Ankit Parikh (A)

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Hugo Albrecht (H)

Drug Discovery and Development Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Clive A Prestidge (CA)

ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Sanjay Garg (S)

Pharmaceutical Innovation and Development (PIDG) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Anton Blencowe (A)

Applied Chemistry and Translational Biomaterials (ACTB) Group, Clinical and Health Sciences, University of South Australia (UniSA), Adelaide, SA 5000, Australia.

Classifications MeSH